Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 19/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424995 | 0.94 | CRBN (0.58) | CRBNDDB1GSPT1TNFIL1B | |
| SCHEMBL14072308 | 0.92 | CRBN (0.47) | CRBNDDB1GSPT1TNFIL1B | |
| SCHEMBL1424338 | 0.91 | DDB1 (0.58) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1424285 | 0.91 | DDB1 (0.60) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1424243 | 0.89 | DDB1 (0.58) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1425003 | 0.89 | CRBN (0.58) | CRBNDDB1GSPT1TNFIL1B | |
| SCHEMBL1424329 | 0.89 | DDB1 (0.64) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1424231 | 0.89 | DDB1 (0.59) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1424341 | 0.88 | DDB1 (0.61) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL14072339 | 0.87 | CRBN (0.56) | CRBNDDB1TNFIL1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2014172429-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2076260-B1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2076260-B1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| WO-2008033567-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | INMT, HNMT, TPMT | CRBN 3001/4885DDB1 3723/4885GSPT1 2801/4885 |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885DDB1 820/4885GSPT1 861/4885 |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885DDB1 820/4885GSPT1 861/4885 |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | INMT, HNMT, TPMT | CRBN 3001/4885DDB1 3723/4885GSPT1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.